Results 191 to 200 of about 21,458 (231)

Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. [PDF]

Toxins (Basel)
Han HS, Kim WS, Lee Y, Won CH, Lee W, Choi SY, Kim BJ.   +6 more
europepmc   +1 more source

A Study of Combined Onabotulinumtoxin A and Hyaluronic Acid Filler for the Treatment of Enlarged Facial Pores. [PDF]

Toxins (Basel)
Vachiramon V, Chirasuthat S, Boonpethkaew S, Sakpuwadol N, Yongpisarn T, Jurairattanaporn N.   +5 more
europepmc   +1 more source

Effectiveness of a Bivalent Recombinant Vaccine on the Production of Neutralizing Antibodies Against BoNT/C, BoNT/D, BoNT/CD e BoNT/DC in Bovines. [PDF]

Vaccines (Basel)
Drigo I, Zandonà L, Tonon E, Capello K, Bano L.   +4 more
europepmc   +1 more source

Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research. [PDF]

Toxins (Basel)
Enemchukwu E, Mohamud H, Sinclair S, Harbour V, Syan R, Kennelly M, Gunamany S.   +6 more
europepmc   +1 more source

The Face of Emotion: Botulinum Toxin, Emotional Anatomy, and Mood Modulation. [PDF]

J Cosmet Dermatol
Vanaria RJ, Chaudry A, Marrero-Perez AC, Lorenc ZP, Nestor MS.   +4 more
europepmc   +1 more source

Effects on equinism of botulinum toxin type and serial cast in children with spastic displegic cerebral palsy

, 2001
Hantamalala Rafidison-Barre
openalex   +1 more source

Different types of botulinum toxin in humans [PDF]

Movement Disorders, 2004
In humans, botulinum neurotoxin (BoNT) serotype A (BoNT/A) is a useful therapeutic tool, but different BoNT serotypes may be useful when a specific immune resistance related to BoNT/A is proved. BoNT serotype F (BoNT/F) was injected into human muscles but its effects are shorter compared to BoNT/A, whereas BoNT serotype B (BoNT/B) is effective in ...
ELEOPRA R, TUGNOLI V, QUATRALE R, ROSSETTO, ORNELLA, MONTECUCCO, CESARE   +4 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F

Neurotoxicity Research, 2006
Botulinum neurotoxin (BoNT) serotype A is commonly used in the treatment of focal dystonia, but some patients are primarily or become secondarily resistant to it. Consequently, other serotypes have to be used when immuno-resistance is proven. In the literature, patients with focal dystonia have been treated with BoNT serotype F with clinical benefit ...
ELEOPRA R, TUGNOLI V, QUATRALE R, ROSSETTO, ORNELLA, MONTECUCCO, CESARE, DRESSLER D.   +5 more
openaire   +4 more sources